Key result
Novel serological biomarker panels achieved an ROC AUC of 1.00 for both early and late-onset preeclampsia, outperforming the benchmark sFlt-1/PlGF ratio (AUC 0.86) in late-onset disease discrimination.
Why the study?
Do multi-omics derived biomarker panels improve the diagnosis of early and late onset preeclampsia compared to the sFlt-1/PlGF ratio?
Case-Control (n=64)
No
Do multi-omics derived biomarker panels improve the diagnosis of early and late onset preeclampsia compared to the sFlt-1/PlGF ratio?
Absolute Event Rate: 1% vs 0.86%
p-value: p=3.65E-4
Multi-omics derived biomarker panels may offer superior diagnostic discrimination for early and late onset preeclampsia compared to the traditional sFlt-1/PlGF ratio.
May support improved preeclampsia discrimination; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Preeclampsia (PE) is a pregnancy-related vascular disorder which is the leading cause of maternal morbidity and mortality. We sought to identify novel serological protein markers to diagnose PE with a multi-'omics' based discovery approach. METHODS: Seven previous placental expression studies were combined for a multiplex analysis, and in parallel, two-dimensional gel electrophoresis was performed to compare serum proteomes in PE and control subjects. The combined biomarker candidates were validated with available ELISA assays using gestational age-matched PE (n=32) and control (n=32) samples. With the validated biomarkers, a genetic algorithm was then used to construct and optimize biomarker panels in PE assessment. RESULTS: In addition to the previously identified biomarkers, the angiogenic and antiangiogenic factors (soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF)), we found 3 up-regulated and 6 down-regulated biomakers in PE sera. Two optimal biomarker panels were developed for early and late onset PE assessment, respectively. CONCLUSIONS: Both early and late onset PE diagnostic panels, constructed with our PE biomarkers, were superior over sFlt-1/PIGF ratio in PE discrimination. The functional significance of these PE biomarkers and their associated pathways were analyzed which may provide new insights into the pathogenesis of PE.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) conducted a case-control in Preeclampsia (n=64). Novel serological protein biomarker panels vs. sFlt-1/PlGF ratio was evaluated on Discrimination of late-onset preeclampsia (ROC AUC) (p=3.65E-4). Novel serological biomarker panels achieved an ROC AUC of 1.00 for both early and late-onset preeclampsia, outperforming the benchmark sFlt-1/PlGF ratio (AUC 0.86) in late-onset disease discrimination.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: